Wachtell Kristian, Devereux Richard B, Lyle Paulette A
Rigshospitalet, Department of Cardiology B2142, The Heart Center, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Curr Cardiol Rep. 2006 Sep;8(5):356-64. doi: 10.1007/s11886-006-0075-1.
Atrial fibrillation, the most common cardiac arrhythmia in clinical practice, causes significant burden to patients and health care systems worldwide. Attention is being paid to prevention of atrial fibrillation using drugs that retard or prevent atrial fibrosis and arrhythmogenic remodeling, which lead to this arrhythmia. Agents that work through the renin-angiotensin-receptor system, the angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are showing promise in animal and human studies.
心房颤动是临床实践中最常见的心律失常，给全球患者和医疗保健系统带来了沉重负担。人们正关注使用能延缓或预防心房纤维化及致心律失常性重塑（这会导致这种心律失常）的药物来预防心房颤动。通过肾素 - 血管紧张素 - 受体系统起作用的药物，即血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂，在动物和人体研究中显示出了前景。
